Article

InSite files with FDA for fluoroquinolone approval

Alameda, CA-InSite Vision Inc. has filed an investigational new drug application with the FDA for ISV-403, its treatment for ocular bacterial infections, under development with Bausch & Lomb.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
John Saharek, president of ImprimisRX, speaks with Ophthalmology Times' David Hutton on three new products the company will be featuring during the American Academy of Ophthalmology's 2021 annual meeting
What keeps you up at night in ophthalmology: Part II
Chris Adams, Diopter Corp CEO
Ramin Valian, of Allergan, discusses pharmaceuticals in the glaucoma industry at Glaucoma 360
Related Content
Outlook Therapeutics stock undergoes 1-for-20 reverse stock split
March 14th 2024

Outlook Therapeutics stock undergoes 1-for-20 reverse stock split

Planning for financial safety in an uncertain year
October 31st 2020

Planning for financial safety in uncertain times

©utah51 / stock.adobe.com
April 26th 2023

The ins and outs of treating ‘financial cataracts’

Over time, markets have proved positive and resilient
March 17th 2023

Over time, markets have proved positive and resilient

Are there alternative opportunities in volatile markets?
October 28th 2022

Are there alternative opportunities in volatile markets?

The sword and shield of investing
May 20th 2022

The sword and shield of investing

© 2025 MJH Life Sciences

All rights reserved.